SCHEMBL19969385

SCHEMBL19969385

Cn1c(=O)c2c(ncn2CCCCCCCCN2CCCC2c2cccnc2)n(C)c1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 1/20 0.50
HTR6 P50406 1/20 0.50
ADORA2B P29275 5/20 0.49
LMNA P02545 3/20 0.49
GAA P10253 1/20 0.49
RXFP1 Q9HBX9 3/20 0.48
MAPK1 P28482 1/20 0.48
TSHR P16473 1/20 0.48
ALDH1A1 P00352 4/20 0.46
CHRNA7 P36544 2/20 0.44
CHRNB2 P17787 2/20 0.44
CHRNB4 P30926 2/20 0.44
CHRNA3 P32297 2/20 0.44
CHRNA4 P43681 2/20 0.44
CHRNA2 Q15822 2/20 0.44
MAPT P10636 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
HTR3E A5X5Y0 1/20 0.44
PSIP1 O75475 1/20 0.44
TRPA1 O75762 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19969383 1.00 HTR7 (0.50) HTR7HTR6ADORA2BLMNAGAA
SCHEMBL19969377 0.99 ADORA2B (0.50) HTR7HTR6ADORA2BLMNAGAA
SCHEMBL19969303 0.94 LMNA (0.51) ADORA2BLMNAGAARXFP1TSHR
SCHEMBL7320325 0.86 TSHR (0.57) HTR7HTR6ADORA2BLMNARXFP1
SCHEMBL7313395 0.84 TSHR (0.57) HTR7HTR6ADORA2BLMNARXFP1
SCHEMBL19969446 0.83 ADORA2A (0.44) LMNAGAARXFP1TSHRALDH1A1
SCHEMBL19969126 0.83 ADORA2A (0.44) LMNAGAARXFP1TSHRALDH1A1
SCHEMBL11150353 0.82 TSHR (0.55) HTR7HTR6ADORA2BLMNARXFP1
SCHEMBL19969450 0.82 ADORA2A (0.44) LMNAGAARXFP1TSHRALDH1A1
SCHEMBL7316547 0.80 ALDH1A1 (0.56) HTR7HTR6ADORA2BLMNARXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11634434-B2 Bifunctional alpha-synuclein binding agents and uses thereof UNIVERSITY OF SASKATCHEWAN (CA) 2023-04-25 US disclosed
US-20200062782-A1 BIFUNCTIONAL ALPHA-SYNUCLEIN BINDING AGENTS AND USES THEREOF UNIVERSITY OF SASKATCHEWAN (CA) 2020-02-27 US disclosed
WO-2018045464-A1 BIFUNCTIONAL ALPHA-SYNUCLEIN BINDING AGENTS AND USES THEREOF UNIVERSITY OF SASKATCHEWAN (CA) 2018-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062782-A1 BIFUNCTIONAL ALPHA-SYNUCLEIN BINDING AGENTS AND USES THEREOF SNCA, PARK7, SYNJ2 HTR7 2811/4885HTR6 2691/4885ADORA2B 2511/4885
US-11634434-B2 Bifunctional alpha-synuclein binding agents and uses thereof SNCA, PARK7, SYNJ2 HTR7 2811/4885HTR6 2691/4885ADORA2B 2511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.